137863-90-2

Basic information

• Product Name: methyl N-valeryl-N-[(2'-cyanobiphenyl-4-yl)methyl]-L-valinate
• Synonyms: methyl N-valeryl-N-[(2'-cyanobiphenyl-4-yl)methyl]-L-valinate;N-[(2'-Cyano[1,1'-biphenyl]-4-yl)methyl]-N-(1-oxopentyl)-L-valine methyl ester;(S)-Methyl 2-(N-((2'-cyanobiphenyl-4-yl)Methyl)pentanaMido) -3-Methylbutanoate;Valsartan Impurity 2;Valsartan impurity 22
• CAS NO: 137863-90-2
• Molecular Formula: C₂₅H₃₀N₂O₃
• Molecular Weight: 407
• EINECS: 1312995-182-4
• Mol File: 137863-90-2.mol
• Article Data: 25

Chemical Properties

• Boiling Point: 579.3±50.0 °C(Predicted)
• Appearance: /
• Density: 1.12±0.1 g/cm3(Predicted)
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), Methanol (slightly)
• PKA: -0.99±0.70(Predicted)
• CAS DataBase Reference: methyl N-valeryl-N-[(2'-cyanobiphenyl-4-yl)methyl]-L-valinate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl N-valeryl-N-[(2'-cyanobiphenyl-4-yl)methyl]-L-valinate(137863-90-2)
• EPA Substance Registry System: methyl N-valeryl-N-[(2'-cyanobiphenyl-4-yl)methyl]-L-valinate(137863-90-2)

Safety Data

• Hazardous Substances Data: 137863-90-2(Hazardous Substances Data)

Usage

Uses

N-[(2''-Cyano[1,1''-biphenyl]-4-yl)methyl]-N-(1-oxopentyl)-L-valine Methyl Ester is an impurity of the drug Valsartan (V095750), which is a nonpeptide angiotensin II AT1-receptor antagonist. Antihypertensive.

Upstream product

• 137863-89-9 N-[(2'-cyanobiphenyl-4-yl)-methyl]-(L)-valine methyl ester 
• 638-29-9 n-valeryl chloride 
• 883223-08-3 (S)-methyl 3-methyl-2-((4-(4,4,5,5-tetramethyl-2,3,2-dioxaborolan-2-yl)benzyl)amino)butanoate 
• 883223-09-4 N-pentanoyl-N-[4-(4′,4′,5′,5′-tetramethyl-1′,3′,2′-dioxaborolan-2'-yl)benzyl]-L-valinemethyl ester 
• 2042-37-7 o-cyanobromobenzene 
• 4070-48-8 L-Valine methyl ester 
• 138500-85-3 4-bromomethylphenylboronic acid pinacol ester 
• 137864-22-3 (S)-2-[(2'-cyanobiphenyl-4-ylmethyl)pentanoylamino]-3-methylbutyric acid benzyl ester 
• 1298055-63-6 C₂₉H₃₆N₂O₃ 
• 1189547-11-2 methyl N-pentanoyl-L-valinate 
• 67-56-1 methanol 
• 138642-62-3 2-Cyanophenylboronic acid 
• 589-15-1 1-bromomethyl-4-bromobenzene 
• 87199-17-5 4-formylphenylboronic acid, 

Downstream Products

• 137863-17-3 methyl N-((2’-(1H-tetrazol-5-yl)-[1,1’-biphenyl]-4-yl)methyl)-N-pentanoyl-L-valinate 
• 137862-53-4 N-pentanoyl-N-[[2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]-methyl]-(L)-valine 
• 443093-86-5 N-((2'-(cyano)-[1,1'-biphenyl]-4-yl)methyl)-N-pentanoyl-L-valine 
• 1298055-61-4 C₃₃H₃₆N₂O₃ 
• 1298055-65-8 C₁₂H₂₃N*C₂₄H₂₈N₂O₃ 
• 944467-25-8 N-valeryl-N-[(2'-(4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl)methyl]-L-valine methyl ester 
• 934736-50-2 N-valeryl-N-[(2'-(4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl)methyl]-L-valine 
• 137862-53-4 valsartan 
• 1353844-74-2 N-(1-oxopentyl)-n-[[2'-(2-tributyltintetrazol-5-yl)-(1,1'-biphenyl)-4-yl]methyl]-(L)-valine methyl ester 

Relevant articles and documents

Improved synthesis of valsartan via nucleophilic aromatic substitution on aryloxazoline

A highly efficient approach to the synthesis of the angiotensin II receptor antagonist valsartan (Diovan), one of the most important agents used in antihypertensive therapy today is described. The formation of the aryl-aryl bond represents the key step of its synthesis, which has been done by simple nucleophelic aromatic substitution on aryloxazoline with good yield and purity. Copyright Taylor & Francis Group, LLC.

A method for preparing methyl valsartan

The invention provides a preparation method of valsartan. The preparation method has the technical effects that amide methyl ester and sodium azide are used as raw materials and are catalyzed by amine salt to carry out tetrazole formation reaction; side effects are minimized by controlling the reaction course; main products are furthest generated; unreacted raw materials are recycled and reused; the yield in the preparation method is increased by more than 10% relative to the yields in existing processes; compared with the existing processes, the method has the effect that plenty of high-toxicity wastewater is no longer generated, and is easy to be widely popularized industrially.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF HYPERTENSION AND MANAGEMENT OF DIABETIC KIDNEY DISEASE

The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing hypertension and diabetic kidney disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of diabetes related renal complications, hypertension, albuminuria, Heart Diseases, ESRD, Kidney GFR complications, Vascular Disease, Ventricular Septal Defect, vascular dilation, high blood pressure, congestive heart failure (CHF), post-myocardial infarction (MI).